| 製品名 | MariTide |
|---|---|
| CAS番号 | 2760218-55-9 |
| 同義語 | MARITIDE; GLP-1/Glucagon receptor agonist; dual incretin agonist |
| 外観 | 白色からオフホワイトの粉末 |
| 純度 | ≥95% (HPLC) |
| 分子式 | Not disclosed |
| 分子量 | Not disclosed |
| 溶解度 | Soluble in water and DMSO |
| ストレージ | Store at -20°C, protect from light |
| パッケージ | 5 g, 10 g, 50 g, or custom |
お困りですか? 弊社チームまでお問い合わせください
Synonyms: MARITIDE; GLP-1/Glucagon receptor agonist; dual incretin agonist
MariTide is a synthetic peptide dual agonist designed to activate both the glucagon-like peptide-1 (GLP-1) and glucagon receptors.
This investigational compound is being developed for the treatment of metabolic disorders, including obesity and type 2 diabetes.
Its dual mechanism of action aims to enhance glucose-dependent insulin secretion while promoting energy expenditure through glucagon receptor activation, offering a promising approach to weight management and glycemic control.
MariTide is a synthetic peptide with a molecular structure that includes a fatty acid moiety for prolonged half-life, similar to other incretin-based therapies. The peptide is composed of amino acids that confer resistance to enzymatic degradation, enhancing its in vivo stability. Its exact sequence and modifications are proprietary, but the compound is supplied as a lyophilized powder with high purity.